STIC-EIC1600/2900 294368

From: CECILIA JAISLE [Cecilia.Jaisle@uspto.gov]
Sent: Thursday, April 30, 2009 1:59 PM
To: STIC-EIC1600/2900
Subject: Search Request, Case/Application No.: 10/812075

Requester: **CECILIA JAISLE (P/1624)**
Art Unit: **GROUP ART UNIT 1624**
Employee Number:
Office Location: **REM 5A11**
Phone Number: **(571)272-9931**

Case/Application number: **10/812075**
Priority Filing Date:
Format for Search Results: **Score**
Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional comments:
Search compounds of claim 2.

Attachment: **Yes (812075, Claims, Page Range14 pages.pdf)**

```
=> fil reg; d stat que l9; fil capl; d que nos l10
FILE 'REGISTRY' ENTERED AT 10:12:23 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 MAY 2009  HIGHEST RN 1142334-49-3
DICTIONARY FILE UPDATES:   4 MAY 2009  HIGHEST RN 1142334-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

L4 STR




```
VAR G1=18/19/21/25/29/32/35/38/40/43
VAR G2=18/19
REP G3=(0-2) CH2
NODE ATTRIBUTES:
NSPEC   IS R      AT  44
CONNECT IS E3  RC AT   2
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  18 19
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  44
```

STEREO ATTRIBUTES: NONE
L9 2063 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 397632 ITERATIONS 2063 ANSWERS
SEARCH TIME: 00.00.42

FILE 'CAPLUS' ENTERED AT 10:12:23 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 5 May 2009 (20090505/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L4 STR
L9 2063 SEA FILE=REGISTRY SSS FUL L4
L10 32 SEA FILE=CAPLUS SPE=ON ABB=ON L9

=> d ibib abs hitstr l10 1-32; fil hom

L10 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:232742 CAPLUS Full-text
DOCUMENT NUMBER: 150:283081
TITLE: Preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the Wnt-β-catenin cellular messaging system
INVENTOR(S): Pelletier, Jeffrey Claude; Felix, Luciana De Araujo; Green, Daniel Michael; Hauze, Diane Barbara; Lundquist Iv, Joseph Theodore; Mann, Charles William; Mehlmann, John Francis; Rogers, John Francis, Jr.; Vera, Matthew

	Douglas; Molinari, Albert John
PATENT ASSIGNEE(S):	Wyeth, John, and Brother Ltd., USA
SOURCE:	PCT Int. Appl., 184pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026326	A1	20090226	WO 2008-US73655	20080820
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090054392	A1	20090226	US 2008-194235	20080819

PRIORITY APPLN. INFO.:		US 2007-965420P	P 20070820
OTHER SOURCE(S):	MARPAT 150:283081		

GI



I



II

AB The title compds. I [T1-T4 = CH or N (wherein two of T1-T4 = N and the remaining two of T1-T4 = CH); Q = a bond, O, N(CH2)rR8 or CR8R9; U = N or CR10; W = CHR5, O or NR5; R1 = H or alkyl; R2 = (un)substituted alkyl; or R1 and R2 when taken together with the ring to which they are attached form bicyclic cycloalkyl or 8-12 membered bicyclic heterocycle; R3 = H, halo, (un)substituted alkyl, etc.; R4 = H, halo, (un)substituted alkyl, etc.; R5 = H, 5-12 membered hetreoaryl, OH, etc.; R6, R7 = H, halo, CN, etc.; R8-R10 = H or (un)substituted alkyl; or R8 and R9 taken together = O; m, n, o, p = 0-2; s

= 0-1; r = 0-3], useful for treating canonical Wnt-β-catenin cellular messaging system-related disorders, were prepared E.g., a multi-step synthesis of (3S)-II, starting from 2-acetylnaphthalene and dimethylformamide-dimethyl acetal, was given. Compds. I were tested in functional Dkk1-LRP5-TCF-Luciferase assay in U2OS cells (data given). Pharmaceutical composition comprising compound I is disclosed.

IT 1123234-21-8P 1123234-24-1P 1123234-26-3P
1123234-30-9P 1123234-33-2P 1123234-36-5P
1123234-39-8P 1123241-14-4P 1123247-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs for treating canonical Wnt-β-catenin cellular messaging system-related disorders)

RN 1123234-21-8 CAPLUS
CN Acetamide, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-24-1 CAPLUS
CN Carbamic acid, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-26-3 CAPLUS
CN Urea, N,N-dimethyl-N'-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-30-9 CAPLUS
CN Urea, N-ethyl-N'-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-33-2 CAPLUS
CN Methanesulfonamide, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-36-5 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-39-8 CAPLUS
CN 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123241-14-4 CAPLUS
CN Carbamic acid, N-[[cis-4-[methyl[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 1123247-30-2 CAPLUS
CN Carbamic acid, N-[[cis-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester (CA INDEX NAME)

Relative stereochemistry.



IT 1123242-97-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs for treating canonical Wnt-β-catenin cellular messaging system-related disorders)
RN 1123242-97-6 CAPLUS
CN Carbamic acid, N-[[trans-4-[methyl[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123242-96-5
CMF C30 H32 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:232741 CAPLUS Full-text
DOCUMENT NUMBER: 150:283080
TITLE: Preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the Wnt-β-catenin cellular messaging system
INVENTOR(S): Pelletier, Jeffrey Claude; Felix, Luciana De Araujo; Green, Daniel Michael; Hauze, Diane Barbara; Lundquist Iv, Joseph Theodore; Mann, Charles William; Mehlmann, John Francis; Rogers, John Francis, Jr.; Vera, Matthew Douglas; Molinari, Albert John
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 184pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026319	A1	20090226	WO 2008-US73644	20080820
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090054392	A1	20090226	US 2008-194235	20080819
PRIORITY APPLN. INFO.:			US 2007-965420P P	20070820

OTHER SOURCE(S): MARPAT 150:283080
GI



I



II

AB The title compds. I [T1-T4 = CH or N (wherein two of T1-T4 = N and the remaining two of T1-T4 = CH); Q = a bond, O, N(CH2)rR8 or CR8R9; U = N or CR10; W = CHR5, O or NR5; R1 = H or alkyl; R2 = (un)substituted alkyl; or R1 and R2 when taken together with the ring to which they are attached form bicyclic cycloalkyl or 8-12 membered bicyclic heterocycle; R3 = H, halo, (un)substituted alkyl, etc.; R4 = H, halo, (un)substituted alkyl, etc.; R5 = H, 5-12 membered hetreoaryl, OH, etc.; R6, R7 = H, halo, CN, etc.; R8-R10 = H or (un)substituted alkyl; or R8 and R9 taken together = O; m, n, o, p = 0-2; s = 0-1; r = 0-3], useful for treating canonical Wnt-β-catenin cellular messaging system-related disorders, were prepared E.g., a multi-step synthesis of (3S)-II, starting from 2-acetylnaphthalene and dimethylformamide-dimethyl acetal, was given. Compds. I were tested in functional Dkk1-LRP5-TCF-Luciferase assay in U2OS cells (data given). Pharmaceutical composition comprising compound I is disclosed.

IT 1123234-21-8P 1123234-24-1P 1123234-26-3P
1123234-30-9P 1123234-33-2P 1123234-36-5P
1123234-39-8P 1123241-14-4P 1123247-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs for treating canonical Wnt-β-catenin cellular messaging system-related disorders)

RN 1123234-21-8 CAPLUS

CN Acetamide, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-24-1 CAPLUS
CN Carbamic acid, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-26-3 CAPLUS
CN Urea, N,N-dimethyl-N'-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-30-9 CAPLUS
CN Urea, N-ethyl-N'-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-33-2 CAPLUS
CN Methanesulfonamide, N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-36-5 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123234-39-8 CAPLUS
CN 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-[trans-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1123241-14-4 CAPLUS

CN Carbamic acid, N-[[cis-4-[methyl[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 1123247-30-2 CAPLUS
CN Carbamic acid, N-[[cis-4-[[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester (CA INDEX NAME)

Relative stereochemistry.



IT 1123242-97-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs for treating canonical Wnt-β-catenin cellular messaging system-related disorders)
RN 1123242-97-6 CAPLUS
CN Carbamic acid, N-[[trans-4-[methyl[4-(2-naphthalenyl)-2-pyrimidinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123242-96-5
CMF C30 H32 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:729540 CAPLUS Full-text
DOCUMENT NUMBER: 149:54023
TITLE: Preparation of novel imidazolones as guanylyl cyclase receptor A (GC-A) agonists
INVENTOR(S): Namikawa, Koji; Shimamoto, Tetsuo; Kitano, Katsuhiko; Koyama, Yoshiaki
PATENT ASSIGNEE(S): Asubio Pharma Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 34pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008137897	A	20080619	JP 2006-322504	20061129

PRIORITY APPLN. INFO.: JP 2006-322504 20061129
OTHER SOURCE(S): MARPAT 149:54023
GI



I

AB Title compds. I (R1, R2, R4-R7 = C1-6 alkyl, C6-14 aromatic hydrocarbyl, H; R3 = C1-10 alkyl, C6-14 aromatic hydrocarbyl, H; X = NH, O), their salts, or their solvates are prepared The imidazolones show diuretic activity, thus useful for treatment of acute heart failure. Thus, 350 mg N-(4-anilino-6-chloro-1,3,5-triazin-2-yl)-L-leucine Me ester was treated with 300 mg guanidine at 100° in propionitrile, then treated with aqueous CF3CO2H to give 348 mg 1-[4-(2-amino-5-isobutyl-4-oxo-4,5-dihydro-1H- imidazol-1-yl)-6-anilino-1,3,5-triazin-2-yl]guanidine ditrifluoroacetate, which showed GC-A receptor agonist activity with ED50 value of 4000 nM in CHO/human GCA (4A) cells.

IT 1033127-69-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (imidazolyltriazinyl)guanidines as guanylyl cyclase receptor
A agonists for treatment of acute heart failure)

RN 1033127-69-3 CAPLUS

CN Guanidine, N-[4-[(5S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazol-1-yl]-6-[[4-[[4-(2-butyl-3-oxo-1-piperazinyl)-6-chloro-2-pyrimidinyl]amino]cyclohexyl]amino]-1,3,5-triazin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1033127-68-2
CMF C29 H44 Cl N15 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 1033127-71-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (imidazolyltriazinyl)guanidines as guanylyl cyclase receptor
A agonists for treatment of acute heart failure)
RN 1033127-71-7 CAPLUS
CN Guanidine, N-[4-[(5S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazol-1-yl]-6-[[4-[[4-(2-butyl-3-oxo-1-piperazinyl)-2-pyrimidinyl]amino]cyclohexyl]amino]-1,3,5-triazin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1033127-70-6
CMF C29 H45 N15 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2